A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lazertinib
Related studies linked through entity extraction aliases.
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
- Status
- RECRUITING
- Phase
- PHASE2
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
- Status
- RECRUITING
- Phase
- PHASE2
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
- Status
- COMPLETED
- Phase
- PHASE1
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
- Status
- COMPLETED
- Phase
- N/A
A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants
- Status
- COMPLETED
- Phase
- PHASE1
Impact of Lazertinib Dose Modification on Effectiveness and Safety
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Lazertinib 160mg in EGFR T790M NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- N/A
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
- Status
- RECRUITING
- Phase
- PHASE2